Allogene Therapeutics Appoints Timothy Moore as Chief Technical Officer
<!-- Name:DistributionId Value:8812455 -->
<!-- Name:EnableQuoteCarouselOnPnr Value:False -->…
Browsing Tag
Allogene
Allogene Therapeutics Presents Interim Phase 1 Data on ALLO-316 in Renal Cell…
<!-- Name:DistributionId Value:8808845 -->
<!-- Name:EnableQuoteCarouselOnPnr Value:False -->…
Allogene Therapeutics Announces Oral Presentation of Phase 1 Data on ALLO-316 at the…
<!-- Name:DistributionId Value:8788429 -->
<!-- Name:EnableQuoteCarouselOnPnr Value:False -->…
Allogene Therapeutics Presents Data on Dagger™, a Next Generation AlloCAR T™ Platform…
<!-- Name:DistributionId Value:8741131 -->
<!-- Name:EnableQuoteCarouselOnPnr Value:False -->…
Allogene Therapeutics to Present at the 41st Annual J.P. Morgan Healthcare Conference
SOUTH SAN FRANCISCO, Calif., Jan. 04, 2023 (GLOBE NEWSWIRE) -- Allogene Therapeutics, Inc. (Nasdaq: ALLO), a clinical-stage biotechnology company pioneering the development of allogeneic…
Allogene Therapeutics R&D Showcase Features Hematologic and Solid Tumor Advances…
Hematology Franchise: Lead CD19 and BCMA Programs Demonstrated Deep, Durable Responses CD19 Program: Phase 1 Studies Support Ongoing ALLO-501A Potentially Pivotal Phase 2 Trial in…
Allogene Therapeutics Initiates Industry’s First Allogeneic CAR T Phase 2 Trial
ALPHA2 Trial, Evaluating ALLO-501A in Relapsed/Refractory Large B Cell Lymphoma Patients, is Designed to Leverage the Ease and Convenience of a Single Dose of ALLO-501AProtocol Supported by…
Allogene Therapeutics Reports Second Quarter 2022 Financial Results
U.S. FDA Clearance on Potential Pivotal Phase 2 Trial of ALLO-501A Anticipated in Coming WeeksExpected to be the Industry’s First Allogeneic CAR T Phase 2 Pivotal TrialClearance to Cover…
Allogene Therapeutics Announces the FDA Granted Regenerative Medicine Advanced…
RMAT Designation Follows Positive Data from ALLO-501A ALPHA2 Trial in Heavily Pretreated Patients with Relapsed or Refractory Large B cell Lymphoma (LBCL) Data Presented at the American…
Allogene Therapeutics Announces Preclinical Publication Highlighting Superiority of…
Results Demonstrated Anti-BCMA CAR T Cells Derived from Healthy Donors Had Better Immune Fitness and Killing ActivityPhase 1 AlloCAR T™ Trials Underway Evaluating ALLO-715 and ALLO-605 for…